Spark Therapeutics Inc. (NASDAQ:ONCE)’s share price shot up 9.3% on Thursday . The stock traded as high as $64.90 and last traded at $63.93, with a volume of 483,642 shares trading hands. The stock had previously closed at $58.49.

ONCE has been the subject of a number of recent research reports. Royal Bank Of Canada initiated coverage on shares of Spark Therapeutics in a report on Tuesday, July 12th. They set an “outperform” rating and a $70.00 price target for the company. Zacks Investment Research upgraded shares of Spark Therapeutics from a “hold” rating to a “buy” rating and set a $66.00 price target for the company in a report on Thursday. Cantor Fitzgerald reiterated a “buy” rating and set a $94.00 price target on shares of Spark Therapeutics in a report on Thursday. Jefferies Group reiterated a “hold” rating on shares of Spark Therapeutics in a report on Sunday, June 12th. Finally, Cowen and Company reiterated a “buy” rating and set a $75.00 price target on shares of Spark Therapeutics in a report on Thursday, May 19th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and eight have given a buy rating to the stock. Spark Therapeutics currently has a consensus rating of “Hold” and an average price target of $61.20.

The firm’s 50-day moving average price is $53.81 and its 200 day moving average price is $41.34. The firm’s market cap is $1.73 billion.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Wednesday, August 10th. The company reported ($1.04) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.97) by $0.07. During the same period last year, the firm earned ($0.60) earnings per share. The business had revenue of $1.29 million for the quarter, compared to the consensus estimate of $1.17 million. The company’s revenue was up .0% compared to the same quarter last year. Equities analysts predict that Spark Therapeutics Inc. will post ($3.76) EPS for the current year.

In other Spark Therapeutics news, major shareholder Hospital Of Philade Children’s sold 1,000,000 shares of the company’s stock in a transaction dated Monday, June 20th. The shares were sold at an average price of $42.30, for a total value of $42,300,000.00. Following the completion of the sale, the insider now directly owns 6,768,707 shares of the company’s stock, valued at approximately $286,316,306.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Anand Mehra sold 500 shares of the company’s stock in a transaction dated Tuesday, May 31st. The shares were sold at an average price of $60.00, for a total transaction of $30,000.00. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in Spark Therapeutics stock. UBS Oconnor LLC acquired a new stake in Spark Therapeutics Inc. (NASDAQ:ONCE) during the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 97,000 shares of the company’s stock, valued at approximately $4,395,000. UBS Oconnor LLC owned about 0.39% of Spark Therapeutics as of its most recent filing with the SEC.

Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.